| Literature DB >> 26254049 |
Katie D White1, Wen-Hung Chung2, Shuen-Iu Hung3, Simon Mallal4, Elizabeth J Phillips5.
Abstract
Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of preventable morbidity, mortality, and cost. Increasingly, genetic variation in the HLA loci is associated with risk of severe reactions, highlighting the importance of T-cell immune responses in the mechanisms of both B cell-mediated and primary T cell-mediated IM-ADRs. In this review we summarize the role of host genetics, microbes, and drugs in IM-ADR development; expand on the existing models of IM-ADR pathogenesis to address multiple unexplained observations; discuss the implications of this work in clinical practice today; and describe future applications for preclinical drug toxicity screening, drug design, and development.Entities:
Keywords: Abacavir; Stevens-Johnson syndrome; T-cell receptor; adverse drug reaction; allopurinol; altered peptide; carbamazepine; drug reaction with eosinophilia and systemic symptoms; hapten; heterologous immunity; human herpesvirus; human leukocyte antigen; major histocompatibility complex; p-i; pharmacogenetics; pharmacogenomics; toxic epidermal necrolysis
Mesh：
Substances：
Year: 2015 PMID： 26254049 PMCID： PMC4577472 DOI： 10.1016/j.jaci.2015.05.050
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN： 0091-6749 Impact factor: 10.793